Assertio Holdings, Inc. (ASRT)
| Market Cap | 151.86M +141.4% |
| Revenue (ttm) | 102.16M -14.2% |
| Net Income | -35.69M |
| EPS | -5.56 |
| Shares Out | 6.46M |
| PE Ratio | n/a |
| Forward PE | 19.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 274,343 |
| Open | 23.48 |
| Previous Close | 23.48 |
| Day's Range | 23.48 - 23.50 |
| 52-Week Range | 8.61 - 23.50 |
| Beta | 0.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2026 |
About ASRT
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;... [Read more]
Financial Performance
In 2025, Assertio Holdings's revenue was $118.71 million, a decrease of -5.00% compared to the previous year's $124.96 million. Losses were -$30.38 million, 40.7% more than in 2024.
Financial StatementsNews
Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful completion of its previously announced merger (the “Merger”) wit...
Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, following an engagement process outlined under the revised merger agreeme...
Assertio and Garda Mutually Agree to Delay Launch of Tender Offer
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio Holdings Quarterly report: Q1 2026
Assertio Holdings has published its Q1 2026 quarterly earnings report on May 8, 2026.
Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (“Garda”) entered into an...
Assertio and Garda Mutually Agree to Extend Tender Offer Deadline
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”)...
Assertio Provides Update on Garda Therapeutics Tender Process
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today provided an update that Garda Therapeutics, Inc. (“Garda”) intends to commence the tende...
Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN® and Additional Products from Assertio
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sal...
Assertio Announces Agreement to be Acquired by Garda Therapeutics
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therape...
Assertio Holdings Proxy statement: Proxy filing
Assertio Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Assertio Holdings Earnings Call Transcript: Q4 2025
Q4 2025 sales declined due to ROLVEDON inventory timing, but full-year sales grew to $117.1M, led by ROLVEDON. 2026 guidance projects $110M–$125M revenue and $28M–$40M adjusted EBITDA, with ROLVEDON as the primary growth driver and legacy assets expected to decline.
Assertio Holdings Annual report: Q4 2025
Assertio Holdings has published its Q4 2025 annual report on March 16, 2026.
Assertio Holdings Earnings release: Q4 2025
Assertio Holdings released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results
LAKE FOREST, Ill--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated pro...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 20...
Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) t...
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolve...
Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (t...
Assertio Holdings Earnings Call Transcript: Q3 2025
Strong Q3 results driven by a Rosedown sales pull forward led to higher revenue and EBITDA, with guidance narrowed for 2025. Rosedown and Synthesan showed growth, while Indocin faced generic pressure. Cash flow will temporarily dip due to sales timing.
Assertio Holdings Quarterly report: Q3 2025
Assertio Holdings has published its Q3 2025 quarterly earnings report on November 10, 2025.
Assertio Holdings Earnings release: Q3 2025
Assertio Holdings released its Q3 2025 earnings on November 10, 2025, summarizing the period's financial results.
Assertio Reports Third Quarter 2025 Financial Results
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated pr...
Assertio Announces Leadership Transition
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the...
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spect...